Are peptides different for women?

For the compounds actually on sale, nobody has published the trials that would answer this: the growth-hormone secretagogues, BPC-157 and TB-500 have no randomised human trial with a strength or muscle-size endpoint in either sex, so there is no male result to compare a female result against. Where sex-specific physiology has been studied in this area, it matters: with oestradiol held constant, postmenopausal women's growth-hormone responses to secretagogues including GHRP-2 were 26-33% of premenopausal women's, a larger difference than most supplement effects.

How under-represented are women in exercise research?

Measurably. An analysis of 972 human-participant articles across three major journals found women averaged 21.9% of participants per article in 1991 and 36.3% in 2021. The gap is worst in small studies: those under roughly 3,000 participants averaged 35.6% women, while very large datasets were near balanced. Small studies are what supplement and training research is made of.

What supplement has the best evidence in women specifically?

Creatine. Women carry roughly 70-80% lower endogenous creatine stores than men, and a meta-analysis of 100 placebo-controlled studies reported no difference in effect size between sexes — meaning the effect, which is small in everyone, is at least documented rather than assumed. A 2021 review in Nutrients covers the pre-menopausal, pregnancy, post-partum and post-menopausal evidence separately; its authors disclose that two of them advise a creatine manufacturer.

Do the female muscle-growth peptide guides online have data behind them?

Almost none, and the exception is not a compound anyone sells. Exactly one research compound in this space has a female-only human trial: ACE-031, a soluble activin receptor, tested in 48 healthy postmenopausal women, where a single dose at the highest level raised total body lean mass 3.3% by DXA and thigh muscle volume 5.1% by MRI at day 29. It is a real positive result in women, and the compound never reached market. No growth-hormone secretagogue, and neither BPC-157 nor TB-500, has any female-specific muscle data at all.

Does menopause change how these compounds would work?

For the growth-hormone secretagogues, the one controlled study says yes and says so strongly. Veldhuis and colleagues clamped oestradiol to comparable concentrations in pre- and postmenopausal women and still found postmenopausal responses at 26-33% of premenopausal across GHRP-2, GHRH and l-arginine, with postmenopausal women also losing the usual ordering of secretagogue potency. Whatever these compounds do, they do not do it identically across the lifespan.

Are these compounds banned for women in tested sport?

Yes, identically. The WADA Prohibited List does not vary by sex. BPC-157 sits at S0, thymosin-beta-4 derivatives such as TB-500 at S2.3, and the growth-hormone secretagogues at S2.2 — prohibited at all times for every athlete in a tested pool.

Peptides for Women: The Research Gap, Counted

Most muscle and recovery evidence was collected in men. We audited who was actually in the studies this field rests on, and read the two that asked about women.

Search for peptides and women and the results split into two kinds of page: a list of compounds with the word "female" added to the headline, and a warning that women should be cautious. Neither is built on female data, because in this corner of the field there is almost none. This page counts what is missing, reads the two studies that did set out to answer women-specific questions, and names the compound in this category with the best sex-specific human evidence — which turns out to be the cheapest one. It is research journalism about research compounds and contains no usage guidance, per our editorial standards.

The gap, measured

The under-representation of women in exercise science is not a talking point; it has been counted. James and colleagues analysed 972 original research articles with human participants published in 1991 and 2021 across the Journal of Applied Physiology, Medicine & Science in Sports & Exercise and the British Journal of Sports Medicine — 2,984,883 participants and 5,735 authors in total. The average share of women participants per article rose from 21.9% in 1991 to 36.3% in 2021. Authorship moved the same way, from 16.4% to 30.9% women, and editorial boards from 13.3% to 41.5% (James et al., Journal of Applied Physiology 2023).

The detail that matters for anyone reading supplement research is where the remaining gap sits. In 2021, large datasets were close to balanced — 50.2% women — but "studies with smaller datasets (i.e., <∼3,000 participants) included less women (35.6 ± 30.6%)". Training studies, supplement crossovers and pharmacokinetic trials all live in that smaller-dataset band. The papers with balanced sex representation are epidemiological; the papers a supplement claim is built from are not.

A companion analysis in PLoS One tested what that costs. Navalta and colleagues took a national health dataset and re-drew it at the sample sizes typical of sport and exercise science — mean 187, median 20 participants — with an imbalanced 33.5% female allocation, and found that statistical decisions changed at both the mean and median sample sizes (Navalta et al., PLoS One 2023). The sex-data gap is not only a fairness problem. At the sample sizes this field actually uses, it changes what the studies conclude.

What the studies behind this field say about who was in them

We read the participant descriptions in the human studies cited across MuscleLedger's ledger pages. This is what they report.

Study	Population as described	Sex reported?
Granhall et al. 2019 — oral semaglutide, first-in-human and multiple-dose	135 healthy males; then 84 healthy males and 23 males with type 2 diabetes	Yes — all male
Shaw et al. 2017 — vitamin C-enriched gelatin and collagen synthesis	"Eight healthy male subjects"	Yes — all male
Veldhuis et al. 2007 — GHRP-2, GHRH and l-arginine under oestradiol clamp	Pre- and postmenopausal women	Yes — all female
Teichman et al. 2006 — CJC-1295 in healthy adults	"Healthy subjects, ages 21-61 yr"	Not stated in the abstract
Beck et al. 2014 — ipamorelin for postoperative ileus	117 adults undergoing bowel resection	Not stated in the abstract
Liu et al. 2007 — growth hormone in the healthy elderly, 18 study populations	220 participants, mean age 69, mean BMI 28	Not stated in the abstract
Falutz et al. 2008 — tesamorelin, 52-week extension	410 HIV patients with central fat accumulation	Not stated in the abstract

Four of the seven do not state sex composition in the abstract at all. Of the three that do, two enrolled only men and the third only women. That is the evidence base underneath every "best peptides for women" list currently ranking.

The one study that asked

The exception is worth reading closely, because it is also the strongest sex-specific finding in the growth-hormone-secretagogue literature.

Veldhuis and colleagues at the Mayo Clinic compared growth-hormone secretion in pre- and postmenopausal women under a controlled oestradiol repletion protocol — that is, with oestradiol, testosterone and sex-hormone-binding globulin brought to comparable concentrations, so that menopausal status rather than circulating oestrogen was the variable. Across all secretagogues tested, including GHRP-2, "GH responses in POST subjects were only 26-33% of those in PRE", and postmenopausal women "lost the PRE order of secretagogue potency (GHRP-2 > GHRH = l-arginine)" (Veldhuis et al., JCEM 2007).

Two things follow. First, a threefold difference in hormonal response between two groups of women is larger than the effect size of almost any supplement in this field — which means "does it work in women" is not one question but several, sorted by hormonal status rather than by sex. Second, the ordering of the secretagogues themselves changed. The hierarchy that the marketing for these compounds is built on was measured in a population where it holds; in postmenopausal women it did not hold.

The one research compound with a female-only trial

There is exactly one, and it is not on any product page, because it is not for sale.

ACE-031 is a soluble form of activin receptor type IIB — a myostatin-pathway drug rather than a growth-hormone one. Its single ascending-dose study was conducted entirely in women: 48 healthy postmenopausal volunteers, double-blind, placebo-controlled, randomised 3:1. At day 29 in the highest-dose group, mean total body lean mass was up 3.3% by DXA (p = 0.03) and thigh muscle volume up 5.1% by MRI (p = 0.03), with adverse events limited in that study to injection-site erythema (Attie et al., Muscle & Nerve 2013).

Two things make this the most instructive entry on the page. It is the only place in this literature where a research compound was shown to increase muscle in women by direct imaging rather than by inference — and imaging is the endpoint our evidence ledger grades highest. And ACE-031 is not available: its development programme did not continue to approval and the compound is not marketed anywhere. The one female result worth having belongs to a drug nobody can buy, while the compounds that are sold have no female data whatever.

Neither BPC-157 nor TB-500 has a female-specific result. Nor does CJC-1295, ipamorelin, sermorelin, GHRP-2, GHRP-6 or IGF-1 LR3 — none of them has been tested for muscle in women, because none has been tested for muscle in anyone.

The compound that does have female data

Creatine is the outlier, and it is the one this site's evidence ledger scores highest.

The strongest recent evidence is female-specific and recent. A 2026 systematic review and meta-analysis in the Journal of the International Society of Sports Nutrition pooled seven randomised placebo-controlled trials in postmenopausal women — 608 randomised, median duration 38 weeks, mean age about 62. Lean mass favoured creatine by 0.37 kg (95% CI +0.05 to +0.69) across five trials, and leg-press one-repetition maximum by 7.5 kg (95% CI +2.2 to +12.8) across three. Benefits appeared where creatine was combined with resistance training; trials using low doses without training showed no measurable effect, bone density was unchanged overall, and adverse events were mild and similar to placebo (Naddafha et al., JISSN 2026). The reader should also know that the authors lead creatine-industry-funded organisations, which the paper discloses.

Note the size of it: 0.37 kg of lean mass over a median 38 weeks, with a confidence interval that nearly touches zero. That is the best female-specific muscle result in this entire field, and it is small — which is the honest benchmark against which every peptide claim aimed at women should be read.

Women carry roughly 70-80% lower endogenous creatine stores than men, which is a physiological reason to expect the response to differ (Smith-Ryan et al., Nutrients 2021, PMC7998865). The 2021 review covers pre-menopause, menses, pregnancy, post-partum and post-menopause separately, reports that supplementation "among pre-menopausal females appears to be effective for improving strength and exercise performance", and notes effects on skeletal muscle size and function in postmenopausal women at what it describes as high doses, with favourable bone effects when combined with resistance training. Two of its four authors disclose that they serve as scientific advisors to a creatine manufacturer, which is stated in the paper and belongs in any honest summary of it.

Against that, the largest meta-analysis of the older literature — 100 placebo-controlled studies, 163 body-composition outcomes — found the effect on body composition small in everyone (effect size 0.17) and reported "no evidence in the literature of an effect of gender or training status on effect size following creatine supplementation" (Branch, International Journal of Sport Nutrition and Exercise Metabolism 2003). Read together, the two papers say something unglamorous and useful: the effect is modest, it has been measured in women, and it does not appear to be smaller in them. MuscleLedger's comparison of creatine against the research compounds works through how far that evidence reaches.

What a female-specific guide would need to contain

Not a different compound list. A different set of studies — trials that report outcomes for women separately, that record menstrual-cycle phase or menopausal status, and that are powered to detect a difference within the female arm rather than pooling it. Exactly one such trial exists in this compound class and it belongs to ACE-031, a drug that is not on the market. For every compound a reader can actually obtain, our ledger's 1-out-of-5 scores reflect an absence of data rather than a demonstrated failure.

The banned-substance position, by contrast, is identical across sexes and worth stating plainly: the WADA Prohibited List does not vary by sex, and BPC-157 (S0), thymosin-beta-4 derivatives including TB-500 (S2.3) and the growth-hormone secretagogues (S2.2) are prohibited at all times for every athlete in a tested pool. Our page on peptides and drug testing covers which tests look for them.

What would change this page

Any randomised trial in women, in this compound class, with a muscle, strength or recovery endpoint. One would be a start. Until then, the most accurate thing a publication can tell a woman researching this category is which claims were measured in someone like her — and the answer, for the injectables, is none of them.